Minimal manifestation status and prednisone withdrawal in the MGTX trial.
Ikjae LeeHui-Chien KuoInmaculada B AbanGary R CutterTarrant McPhersonHenry J KaminskiJon SussmanPhilipp StröbelJoel OgerGabriel CeaJeannine M HeckmannAmelia EvoliWilfred NixEmma CiafaloniGiovanni AntoniniRawiphan WitoonpanichJohn O KingSaid R BeydounColin H ChalkAlexandru C BarboiAnthony A AmatoAziz I ShaibaniBashar KatirjiBryan R F LeckyCamilla BuckleyAngela VincentElza Dias-TostaHiroaki YoshikawaMarcia Waddington-CruzMichael T PulleyMichael H RivnerMaria JędrzejowskaRobert M PascuzziCarlayne E JacksonJan J G VerschuurenJanice M MasseyJohn T KisselLineu C WerneckMichael BenatarRichard J BarohnRup TandanTahseen MozaffarRobin ConwitGreg MinismanJoshua R SonettGil I Wolfenull nullPublished in: Neurology (2020)
This study provides Class II evidence that for patients with generalized MG with AChR antibody, those receiving thymectomy plus prednisone are more likely to attain sustained MMS and complete prednisone withdrawal than those on prednisone alone.